PDE5A and androgen insensitivity syndrome: However, the present review had several limitations including the scarcity of clinical studies concerning the role of PDE5 inhibitors in the management of AIS, and the long-term follow-up of AIS patients on PDE5 inhibitors were poorly estimated.